Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +9.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.10 | N/A | +9.09% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about future developments. They emphasized their commitment to advancing their projects despite current challenges.
Management highlighted ongoing efforts to advance their pipeline.
They acknowledged challenges but remain focused on long-term goals.
The earnings report shows that while Soleno Therapeutics managed to beat EPS expectations, the lack of revenue data and no guidance update may raise concerns among investors. The stock's decline of 3.49% suggests that the market is reacting negatively to the uncertainty surrounding the company's future performance and financial outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021